Doctors Reverse Kidney Failure In An HIV-Infected Patient

September 17, 1998

In the first documented case of its kind, doctors at the University of Maryland Medical Center have been able to reverse kidney failure in an HIV-infected patient by putting the patient on highly active, triple-drug antiretroviral therapy. This case, published in the September 5, 1998, issue of The Lancet, provides the first evidence of a connection between highly active antiretroviral therapy and a dramatic improvement in kidney function in an AIDS patient who had started dialysis. It also suggests that the therapy may eliminate the need for long-term dialysis in HIV patients, although more study is needed.

"It has been the feeling among doctors who treat HIV patients that current antiretroviral therapy may help prevent kidney failure, but it had never been documented," said Emilio Ramos, M.D., a nephrologist at the University of Maryland Medical Center and associate professor at the University of Maryland School of Medicine. "Now we are beginning a study to look at patients with HIV and kidney disease to determine whether they could benefit from highly active antiretroviral therapy."

About 10 percent of patients with HIV infection develop kidney failure. Dr. Ramos says the antiretroviral therapy will not reverse kidney failure in patients who have been on dialysis for a long time and whose kidneys have deteriorated. He believes it is most effective in the early stages of kidney failure, as was the case with this particular patient.

The patient, a 37-year-old African-American male, was unaware of his HIV status when he first came to the medical center. A kidney biopsy revealed that his kidney failure was HIV-related. One week before going on dialysis, he was put on therapy of 20 mg of stavudine a day, 50 mg of larnivudine a day and 1,250 mg of nelfinavir twice daily.

Thirteen weeks later, the patient's kidneys regained normal function and hemodialysis was stopped. In addition, the patient's viral load decreased from more than 900,000 copies/ml to 500 copies/ml. A repeat kidney biopsy also revealed that inflammation on the kidney had almost completely disappeared.

"This case is encouraging, because it implies that even a late stage complication of HIV, such as kidney failure, can be reversed with these powerful drugs. It provides more hope for our patients," says Lori Fantry, M.D., an AIDS specialist at the University of Maryland Medical Center and assistant professor of medicine at the University of Maryland School of Medicine.

"Antiviral medications cost about $10,000 per year. They are very expensive but keeping a patient on dialysis for the rest of his life is also very costly," says Ravinder K. Wali, M.D., lead author of the article and fellow in the Division of Nephrology at the University of Maryland Medical Center. "This case showed that therapy may eliminate the need for long-term dialysis in some HIV patients." Dialysis costs more than $40,000 per year.
Contact: Ellen Beth Levitt
Ira Allen
Barbara Crawford
(410) 328-8919

University of Maryland Medical Center

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to